Abstract
Background: Clinical guidelines for decision-making in chronic kidney disease (CKD) consider parathormone (PTH) levels. The measured PTH values differ if novel full length PTH(1-84) assays are used instead of earlier intact iPTH assays. In this study we analyzed how the classification of CKD patients alters when iPTH assays are switched to PTH(1-84) assays.
Methods: Plasma samples were collected prior to dialysis sessions from 110 consecutive CKD patients on maintenance hemodialysis. PTH levels were determined with iPTH assays (Elecsys, Architect and DiaSorin Liaison N-tact) and PTH(1-84) assays (Elecsys and Liaison). Using KDIGO guidelines patients were classified as being below, above and in the recommended target range (RTR) of PTH. The results of classification with different assays were evaluated and, a novel calculation method of RTR was implemented.
Results: The prevalence of patients with PTH in RTR is comparable with each assay, but the individual patients differed. PTH(1-84) Elecsys and Liaison assays classified more patients as being below RTR than iPTH Elecsys and Architect but not Liaison N-tact assay (27.3%, 22.7% vs. 41%, 31.8%, and 36.4%, respectively). In turn, PTH(1-84) Elecsys and Liaison assays identified less CKD patients with PTH above the RTR than iPTH except N-tact assays (6.4%, 10% vs. 16.3%, 19%, and 6.3%, respectively). Using our calculation method, our discrimination values for PTH(1-84) assays to achieve classification identical to that with iPTH Elecsys were lower than those recommended by the manufacturer.
Conclusions: Current guidelines for the treatment of secondary hyperparathyroidism in CKD should consider the type of assays used for PTH measurement. Each laboratory should assess its own RTR for PTH tests to achieve comparable classification. The presented calculation is simple, it mimics an everyday situation, switching from one assay to another one, and provides useful RTR values for PTH tests.
This work was granted by TÁMOP 4.2.2.B-10/1. Attila Patocs is a recipient of the Janos Bolyai fellowship.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Friedman PA, Goodman WG. PTH(1-84)/PTH(7–84): a balance of power. Am J Physiol Renal Physiol 2006;290:F975–84.10.1152/ajprenal.00336.2005Search in Google Scholar
2. Stokes FJ, Ivanov P, Bailey LM, Fraser WD. The effects of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism. Clin Chem 2011;57:138–40.10.1373/clinchem.2010.157289http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000285686100024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed
3. Sturgeon CM, Seth J. Why do immunoassays for tumour markers give differing results? A view from the UK National External Quality Assessment Schemes. Eur J Clin Chem Clin Biochem 1996;34:755–9.Search in Google Scholar PubMed
4. Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 2008;51:987–95.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000256551700015&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1053/j.ajkd.2008.01.017Search in Google Scholar PubMed
5. Torres PU. The need for reliable serum parathyroid hormone measurements. Kidney Int 2006;70:240–3.10.1038/sj.ki.5001658Search in Google Scholar PubMed
6. National Institute for Health and Clinical Excellence. NICE Technology Appraisal Guidance 117. Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Patients with End-Stage Renal Disease on Maintenance Dialysis Therapy, 2007. Available from: http://guidance.nice.org.uk/nicemedia/live/11608/33857/33857.pdf. Accessed 10 January, 2011.Search in Google Scholar
7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009;113:S1–130.Search in Google Scholar
8. Steddon S, Sharples E. Renal Association Clinical Practice Guideline: CKD-Mineral and Bone Disorders (CKD-MBD), 2011. Available from: http://www.renal.org/clinical/GuidelinesSection/CKD-MBD.aspx. Accessed 10 September.10.1159/000328066Search in Google Scholar
9. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137–47.10.7326/0003-4819-139-2-200307150-00013Search in Google Scholar PubMed
10. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease 2003. Am J Kidney Dis 2003;42:S1–201.10.1016/S0272-6386(03)00905-3Search in Google Scholar
11. Waller S, Ridout D, Cantor T, Rees L. Differences between “intact” PTH and 1-84 PTH assays in chronic renal failure and dialysis. Pediatr Nephrol 2005;20:197–9.10.1007/s00467-004-1735-2Search in Google Scholar PubMed
12. Gao P, Scheibel S, D’Amour P, John MR, Rao SD, Schmidt-Gayk H, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605–14.10.1359/jbmr.2001.16.4.605Search in Google Scholar PubMed
13. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84:4287–90.10.1210/jcem.84.11.6236Search in Google Scholar PubMed
14. La’ulu SL, Roberts WL. Performance characteristics of six intact parathyroid hormone assays. Am J Clin Pathol 2010;134: 930–8.10.1309/AJCPLGCZR7IPVHA7Search in Google Scholar PubMed
15. Taniguchi M, Tanaka M, Hamano T, Nakanishi S, Fujii H, Kato H, et al. Comparison between whole and intact parathyroid hormone assays. Ther Apher Dial 2011;15(Suppl 1): 42–9.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000292544600010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1111/j.1744-9987.2011.00926.xSearch in Google Scholar PubMed
16. Almond A, Ellis AR, Walker SW. On behalf of the scottish clinical biochemistry managed diagnostic network. Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease. Ann Clin Biochem 2012;49:63–7.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000299984500010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1258/acb.2011.011094Search in Google Scholar PubMed
17. Sturgeon CM, Sprague SM, Metcalfe W. Variation in parathyroid hormone immunoassay results – a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant 2011;26:3440–5.10.1093/ndt/gfr614Search in Google Scholar PubMed PubMed Central
18. Souberbielle J-C, Cavalier E, Jean G. Interpretation of serum parathyroid hormone concentrations in dialysis patients: what do the KDIGO guidelines change for the clinical laboratory? Clin Chem Lab Med 2010;48:769–74.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000279342700006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar PubMed
19. Cantor T, Yang Z, Caraiani N, Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 2006;52: 1771–6.10.1373/clinchem.2006.071589Search in Google Scholar PubMed
20. Cavalier E, Delanaye P, Vranken L, Bekaert AC, Carlisi A, Chapelle JP, et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transplant 2012;27:1950–6.10.1093/ndt/gfr535Search in Google Scholar PubMed
©2013 by Walter de Gruyter Berlin Boston